AGP Executive Report
Last update: 8 minutes agoPTSD Treatment Breakthrough: A Nature Medicine trial found prescription dronabinol (THC) cut PTSD nightmare frequency and intensity, with over a third reporting no nightmares after 10 weeks. Cardiovascular Research: UC San Francisco-led research in the Journal of the American College of Cardiology reported inhaled cannabis was linked to about 9% fewer premature heartbeats on days participants used versus days they abstained. Federal Research Funding (Canada): Canada announced $24M for the Canadian Cannabis and Brain Health Consortium to study cannabis effects on the brain across ages, including epilepsy, anxiety, PTSD, sleep, mental health, and pregnancy. Market & Corporate Moves: Organigram said its European acquisition of Germany’s Sanity Group boosted quarterly revenues by about $38M and reshaped its growth strategy. Regulatory/Policy Pressure (Texas): Texas health officials warned that some hemp-derived products may still pose risks even after delta-8 and other synthetically derived cannabinoids were reclassified as Schedule 1. Business Rebrand: Splash Beverage Group plans to rename itself Endovia Health Sciences, positioning as a cannabinoid health sciences platform.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
